Ashok Kumar Jain and Amar Nath Mukerji
In liver transplant (LTx) recipient bioavailability of oral Mycophenolate Mofetil (MMF) is less than 48% in first weeks post LTx week. Intravenous (IV) MMF allows 100% bioavailability with higher peak values. Use of MMF in immediate post LTX period allows delayed introduction of tacrolimus which allows preserving the renal function and reversing the pre-existing renal dysfunction promptly after successful LTx without use of antibody preparation and at no risk of precipitating acute cellular rejection.